FDA Grants Orphan-Drug Exclusivity to Recorlev® for Endogenous Cushing’s Syndrome Treatment
Xeris Pharmaceuticals has revealed that the FDA has awarded orphan-drug exclusivity for its drug Recorlev® (levoketoconazole) for treating adult patients with endogenous Cushing's syndrome for whom su ...
XORTX Therapeutics Submits Orphan Drug Designation Request for XRx-008 Program to FDA for ADPKD Treatment
XORTX Therapeutics Inc., a late-stage clinical pharma company focused on developing novel therapies to treat progressive kidney disease, has submitted an Orphan Drug Designation request to the U.S. Fo ...
FDA Grants Orphan Drug Status to Beactica’s BEA-17 for Glioblastoma Treatment
Beactica Therapeutics, a Swedish precision oncology company, announced today that the U.S. FDA has designated BEA-17 as an orphan drug for the treatment of glioblastoma (GBM). BEA-17 is a first-of-its ...